董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian Brady | 男 | Non-Executive Chairman of the Board | 47 | 1.50万美元 | 0.0004 | 2026-06-05 |
| Charles Nelson | 男 | Independent Director | 72 | 未披露 | 0.0002 | 2026-06-05 |
| Sylvia Hermina | 女 | Independent Director | 46 | 未披露 | 未持股 | 2026-06-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shahrokh Shabahang | 男 | Chief Innovation Officer | 63 | 32.50万美元 | 0.0007 | 2026-06-05 |
| Brian Brady | 男 | Non-Executive Chairman of the Board | 47 | 1.50万美元 | 0.0004 | 2026-06-05 |
| Thomas J. Farley | 男 | Chief Financial Officer | 52 | 39.50万美元 | 0.0002 | 2026-06-05 |
| Christopher Porcelli | 男 | Chief People Officer and General Counsel | 34 | 未披露 | 未持股 | 2026-06-05 |
| Jeffrey M. Busch | 男 | Interim Chief Executive Officer | 68 | 未披露 | 未持股 | 2026-06-05 |
| Corinne Pankovcin | 女 | Chief Mergers & Acquisitions Officer | 59 | 38.50万美元 | 0.0001 | 2026-06-05 |
董事简历
中英对照 | 中文 | 英文- Brian Brady
-
Brian Brady自2018年12月1日起担任董事。Brady先生自2016年3月起还一直担任Prime梦百合的投资总监，负责管理与该公司所有者家庭的组织和个人投资有关的投资活动。从2011年12月到2016年3月，布雷迪先生担任北方信托（Northern Trust）的Vice President/投资组合经理，在那里他担任投资顾问，包括资产和投资组合管理。Brady先生于2001年毕业于伊利诺伊大学芝加哥分校（University of Illinois at Chicago），获得金融学学士学位，并于2014年获得芝加哥大学（University of Chicago）工商管理硕士学位。
Brian Brady was Director of Investments at a large hospital system from March 2016 to December 2022 and returned to this role in 2026 after serving as President of a family office. In his current role, he is responsible for the management of investment activity related to the organization and personal investments of the family that owns that company. From December 2011 to March 2016, Mr. Brady was the Vice President/Portfolio Manager at a wealth advisory firm, where he served in an investment advisory role, including asset and portfolio management. Mr. Brady graduated in 2001 with a bachelor's degree in finance from the University of Illinois at Chicago and in 2014 with a Master of Business Administration degree from the University of Chicago. Aditxt, Inc. - Brian Brady自2018年12月1日起担任董事。Brady先生自2016年3月起还一直担任Prime梦百合的投资总监，负责管理与该公司所有者家庭的组织和个人投资有关的投资活动。从2011年12月到2016年3月，布雷迪先生担任北方信托（Northern Trust）的Vice President/投资组合经理，在那里他担任投资顾问，包括资产和投资组合管理。Brady先生于2001年毕业于伊利诺伊大学芝加哥分校（University of Illinois at Chicago），获得金融学学士学位，并于2014年获得芝加哥大学（University of Chicago）工商管理硕士学位。
- Brian Brady was Director of Investments at a large hospital system from March 2016 to December 2022 and returned to this role in 2026 after serving as President of a family office. In his current role, he is responsible for the management of investment activity related to the organization and personal investments of the family that owns that company. From December 2011 to March 2016, Mr. Brady was the Vice President/Portfolio Manager at a wealth advisory firm, where he served in an investment advisory role, including asset and portfolio management. Mr. Brady graduated in 2001 with a bachelor's degree in finance from the University of Illinois at Chicago and in 2014 with a Master of Business Administration degree from the University of Chicago. Aditxt, Inc.
- Charles Nelson
-
Charles Nelson，在2020年9月至2023年9月期间担任公司顾问。他的金融生涯始于美国国际集团的市场代表，并于1979年加入Dean Witter Reynolds，担任财务顾问，与高净值和机构客户合作。1980年，他加入Drexel Burnham和Lambert，随后，在Ladenberg Thalmann，然后在Auerbach Pollack和Richardson发起股权和投资银行交易。在过去的20年中，Nelson先生通过私募股权和公开融资（包括在纳斯达克和纽约证券交易所上市）参与了金融科技、医疗保健和生物制药领域公司的融资。
Charles Nelson was a consultant to the Company from September 2020 through September 2023. He began his financial career as a market representative with American International Group and in 1979 joined Dean Witter Reynolds as a Financial Advisor, working with high net worth and institutional clients. In 1980, he joined Drexel Burnham and Lambert, and subsequently, at Ladenberg Thalmann and then at Auerbach Pollack and Richardson originating equity and investment banking transactions. Over the last 20 years, Mr. Nelson has been involved with financing companies in the fintech, healthcare and bio pharma spaces through private equity and public financing including listings on the Nasdaq and the NYSE. - Charles Nelson，在2020年9月至2023年9月期间担任公司顾问。他的金融生涯始于美国国际集团的市场代表，并于1979年加入Dean Witter Reynolds，担任财务顾问，与高净值和机构客户合作。1980年，他加入Drexel Burnham和Lambert，随后，在Ladenberg Thalmann，然后在Auerbach Pollack和Richardson发起股权和投资银行交易。在过去的20年中，Nelson先生通过私募股权和公开融资（包括在纳斯达克和纽约证券交易所上市）参与了金融科技、医疗保健和生物制药领域公司的融资。
- Charles Nelson was a consultant to the Company from September 2020 through September 2023. He began his financial career as a market representative with American International Group and in 1979 joined Dean Witter Reynolds as a Financial Advisor, working with high net worth and institutional clients. In 1980, he joined Drexel Burnham and Lambert, and subsequently, at Ladenberg Thalmann and then at Auerbach Pollack and Richardson originating equity and investment banking transactions. Over the last 20 years, Mr. Nelson has been involved with financing companies in the fintech, healthcare and bio pharma spaces through private equity and public financing including listings on the Nasdaq and the NYSE.
- Sylvia Hermina
-
Sylvia Hermina，在公司治理、并购和股东关系方面为上市公司提供咨询服务方面拥有超过20年的经验。Hermina女士目前担任治理和代理征集公司Kingsdale Advisors的高级副总裁。在加入Kingsdale Advisors之前，Hermina女士曾担任Laurel Hill Advisory Group，LLC（一家股东沟通和咨询公司）的高级副总裁；Altman Group，Inc.（一家代理咨询公司）的董事总经理。她还担任过Georgeson Shareholder Communications和Corporate Investor Communications，Inc.的高级职务。Hermina女士拥有蒙特克莱尔州立大学工商管理、管理和市场营销理学学士学位。Sylvia是美国国家投资者关系研究所（NIRI）公司治理协会（Society of Corporate Governance，Society）的成员。
Sylvia Hermina has over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations. Ms. Hermina currently serves as Senior Vice President of Kingsdale Advisors, a governance and proxy solicitation firm. Prior to joining Kingsdale Advisors, Ms. Hermina served as Senior Vice President of Laurel Hill Advisory Group, LLC a shareholder communications and advisory firm; Managing Director of The Altman Group, Inc. a proxy advisory firm. She also held senior positions Georgeson Shareholder Communications and Corporate Investor Communications, Inc. Ms. Hermina holds a Bachelor of Science degree in Business Administration, Management and Marketing from Montclair State University. Sylvia is a member of the Society of Corporate Governance (Society), the National Investor Relations Institute (NIRI) and Chief. - Sylvia Hermina，在公司治理、并购和股东关系方面为上市公司提供咨询服务方面拥有超过20年的经验。Hermina女士目前担任治理和代理征集公司Kingsdale Advisors的高级副总裁。在加入Kingsdale Advisors之前，Hermina女士曾担任Laurel Hill Advisory Group，LLC（一家股东沟通和咨询公司）的高级副总裁；Altman Group，Inc.（一家代理咨询公司）的董事总经理。她还担任过Georgeson Shareholder Communications和Corporate Investor Communications，Inc.的高级职务。Hermina女士拥有蒙特克莱尔州立大学工商管理、管理和市场营销理学学士学位。Sylvia是美国国家投资者关系研究所（NIRI）公司治理协会（Society of Corporate Governance，Society）的成员。
- Sylvia Hermina has over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations. Ms. Hermina currently serves as Senior Vice President of Kingsdale Advisors, a governance and proxy solicitation firm. Prior to joining Kingsdale Advisors, Ms. Hermina served as Senior Vice President of Laurel Hill Advisory Group, LLC a shareholder communications and advisory firm; Managing Director of The Altman Group, Inc. a proxy advisory firm. She also held senior positions Georgeson Shareholder Communications and Corporate Investor Communications, Inc. Ms. Hermina holds a Bachelor of Science degree in Business Administration, Management and Marketing from Montclair State University. Sylvia is a member of the Society of Corporate Governance (Society), the National Investor Relations Institute (NIRI) and Chief.
高管简历
中英对照 | 中文 | 英文- Shahrokh Shabahang
自成立以来，Shahrokh Shabahang一直是我们的首席创新官兼董事。2009年，Shabahang博士联合创立了Sekris Biomedical Inc.，以孵化免疫治疗技术。自成立以来，他担任其董事会主席兼首席执行官。Shabahang博士于2004年加入Genelux Corporation，领导其临床开发计划并担任董事会秘书。Genelux开发了一种用于治疗癌症的溶瘤病毒技术，由Shabahang博士共同发明。在他从2004年到2007年的任期内，Genelux筹集了2000多万美元，并获得了监管机构的批准，开始在欧洲对化疗没有反应的患者进行首次人体临床研究。2001年，Shabahang博士成为Loma Linda University“；LLU”；的微生物与分子生物学实验室主任。他领导了一种用于治疗牙科感染的抗菌治疗剂的研究与开发，该公司由最大的牙科分销公司之一授权和销售。Shabahang博士从1982年到1984年就读于加州大学圣巴巴拉分校（University of California，Santa Barbara），后来于1987年获得太平洋大学（University of Pacific）的博士学位。他于2001年在LLU获得微生物学和分子遗传学博士学位。同年，他在LLU建立了实验室，研究传染病和宿主免疫反应。
Shahrokh Shabahang co founded Sekris Biomedical Inc. to incubate immunotherapy technologies. He served as its Chairman of the board and Chief Executive Officer since its inception. In 2004, Dr. Shabahang joined Genelux Corporation to lead its clinical development program and to serve as board secretary. Genelux developed an oncolytic virus technology for treatment of cancer, co invented by Dr. Shabahang. During his tenure from 2004 2007, Genelux raised $20M+ and obtained regulatory approval to initiate First In Human clinical studies in Europe with patients who had not responded to chemotherapy. In 2001, Dr. Shabahang became the Director of the Microbiology and Molecular Biology Lab at Loma Linda University ("LLU"). He led the research and development of an antimicrobial therapeutic agent for treatment of dental infections, which was licensed and marketed by one of the largest dental distribution companies. Dr. Shabahang attended the University of California, Santa Barbara from 1982 to 1984 and later received his DDS from the University of Pacific in 1987. He earned his PhD in Microbiology and Molecular Genetics at LLU in 2001. During the same year, he established his laboratory at LLU to study infectious diseases and host immune responses.- 自成立以来，Shahrokh Shabahang一直是我们的首席创新官兼董事。2009年，Shabahang博士联合创立了Sekris Biomedical Inc.，以孵化免疫治疗技术。自成立以来，他担任其董事会主席兼首席执行官。Shabahang博士于2004年加入Genelux Corporation，领导其临床开发计划并担任董事会秘书。Genelux开发了一种用于治疗癌症的溶瘤病毒技术，由Shabahang博士共同发明。在他从2004年到2007年的任期内，Genelux筹集了2000多万美元，并获得了监管机构的批准，开始在欧洲对化疗没有反应的患者进行首次人体临床研究。2001年，Shabahang博士成为Loma Linda University“；LLU”；的微生物与分子生物学实验室主任。他领导了一种用于治疗牙科感染的抗菌治疗剂的研究与开发，该公司由最大的牙科分销公司之一授权和销售。Shabahang博士从1982年到1984年就读于加州大学圣巴巴拉分校（University of California，Santa Barbara），后来于1987年获得太平洋大学（University of Pacific）的博士学位。他于2001年在LLU获得微生物学和分子遗传学博士学位。同年，他在LLU建立了实验室，研究传染病和宿主免疫反应。
- Shahrokh Shabahang co founded Sekris Biomedical Inc. to incubate immunotherapy technologies. He served as its Chairman of the board and Chief Executive Officer since its inception. In 2004, Dr. Shabahang joined Genelux Corporation to lead its clinical development program and to serve as board secretary. Genelux developed an oncolytic virus technology for treatment of cancer, co invented by Dr. Shabahang. During his tenure from 2004 2007, Genelux raised $20M+ and obtained regulatory approval to initiate First In Human clinical studies in Europe with patients who had not responded to chemotherapy. In 2001, Dr. Shabahang became the Director of the Microbiology and Molecular Biology Lab at Loma Linda University ("LLU"). He led the research and development of an antimicrobial therapeutic agent for treatment of dental infections, which was licensed and marketed by one of the largest dental distribution companies. Dr. Shabahang attended the University of California, Santa Barbara from 1982 to 1984 and later received his DDS from the University of Pacific in 1987. He earned his PhD in Microbiology and Molecular Genetics at LLU in 2001. During the same year, he established his laboratory at LLU to study infectious diseases and host immune responses.
- Brian Brady
Brian Brady自2018年12月1日起担任董事。Brady先生自2016年3月起还一直担任Prime梦百合的投资总监，负责管理与该公司所有者家庭的组织和个人投资有关的投资活动。从2011年12月到2016年3月，布雷迪先生担任北方信托（Northern Trust）的Vice President/投资组合经理，在那里他担任投资顾问，包括资产和投资组合管理。Brady先生于2001年毕业于伊利诺伊大学芝加哥分校（University of Illinois at Chicago），获得金融学学士学位，并于2014年获得芝加哥大学（University of Chicago）工商管理硕士学位。
Brian Brady was Director of Investments at a large hospital system from March 2016 to December 2022 and returned to this role in 2026 after serving as President of a family office. In his current role, he is responsible for the management of investment activity related to the organization and personal investments of the family that owns that company. From December 2011 to March 2016, Mr. Brady was the Vice President/Portfolio Manager at a wealth advisory firm, where he served in an investment advisory role, including asset and portfolio management. Mr. Brady graduated in 2001 with a bachelor's degree in finance from the University of Illinois at Chicago and in 2014 with a Master of Business Administration degree from the University of Chicago. Aditxt, Inc.- Brian Brady自2018年12月1日起担任董事。Brady先生自2016年3月起还一直担任Prime梦百合的投资总监，负责管理与该公司所有者家庭的组织和个人投资有关的投资活动。从2011年12月到2016年3月，布雷迪先生担任北方信托（Northern Trust）的Vice President/投资组合经理，在那里他担任投资顾问，包括资产和投资组合管理。Brady先生于2001年毕业于伊利诺伊大学芝加哥分校（University of Illinois at Chicago），获得金融学学士学位，并于2014年获得芝加哥大学（University of Chicago）工商管理硕士学位。
- Brian Brady was Director of Investments at a large hospital system from March 2016 to December 2022 and returned to this role in 2026 after serving as President of a family office. In his current role, he is responsible for the management of investment activity related to the organization and personal investments of the family that owns that company. From December 2011 to March 2016, Mr. Brady was the Vice President/Portfolio Manager at a wealth advisory firm, where he served in an investment advisory role, including asset and portfolio management. Mr. Brady graduated in 2001 with a bachelor's degree in finance from the University of Illinois at Chicago and in 2014 with a Master of Business Administration degree from the University of Chicago. Aditxt, Inc.
- Thomas J. Farley
自2021年9月起担任首席财务官。在此之前，法利先生于2020年10月至2021年9月担任首席会计干事兼主计长。2015年12月至2020年6月，法利先生担任美国商业发展公司（“BDCA”）的财务总监，该公司是一家公开上市的商业发展公司。在此之前，2011年1月至2015年8月，Farley先生是BlackRock Capital Investment Corporation（纳斯达克股票代码：BKCC）的高级财务总监。在加入黑岩凯尔索资本投资公司之前，法利先生是PineBridge Investments新兴市场业务的高级财务总监。Farley先生在PineBridge任职之前也是Bessemer Venture Partners的会计经理。法利的职业生涯始于1996年至2001年的普华永道会计师事务所。法利先生在长岛大学获得会计学学士学位，是一名注册会计师。
Thomas J. Farley was the Principal Accounting Officer and Controller from October of 2020 to September 2021. From December 2015 to June 2020, Mr. Farley was the Controller of Business Development Corporation of America ("BDCA"), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenure at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.- 自2021年9月起担任首席财务官。在此之前，法利先生于2020年10月至2021年9月担任首席会计干事兼主计长。2015年12月至2020年6月，法利先生担任美国商业发展公司（“BDCA”）的财务总监，该公司是一家公开上市的商业发展公司。在此之前，2011年1月至2015年8月，Farley先生是BlackRock Capital Investment Corporation（纳斯达克股票代码：BKCC）的高级财务总监。在加入黑岩凯尔索资本投资公司之前，法利先生是PineBridge Investments新兴市场业务的高级财务总监。Farley先生在PineBridge任职之前也是Bessemer Venture Partners的会计经理。法利的职业生涯始于1996年至2001年的普华永道会计师事务所。法利先生在长岛大学获得会计学学士学位，是一名注册会计师。
- Thomas J. Farley was the Principal Accounting Officer and Controller from October of 2020 to September 2021. From December 2015 to June 2020, Mr. Farley was the Controller of Business Development Corporation of America ("BDCA"), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenure at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.
- Christopher Porcelli
Christopher Porcelli曾在Aterian, Inc.（纳斯达克：ATER）担任高级法律和人力资源职务，包括总法律顾问、人事主管和公司秘书（2023 – 2025）。此前，他是纽约Sidley Austin LLP并购集团的合伙人，也是纽约Cadwalader，Wickersham & Taft LLP的企业合伙人。他在纽约大学法学院获得法学博士学位，在圣约翰大学获得学士学位，并获准在纽约执业。
Christopher Porcelli served in senior legal and HR roles at Aterian, Inc. (Nasdaq: ATER), including General Counsel, Head of People & Corporate Secretary (2023–2025). Previously, he was an associate in the M&A group at Sidley Austin LLP in New York and a corporate associate at Cadwalader, Wickersham & Taft LLP in New York. He received his J.D. from New York University School of Law and his B.A. from St. John's University and is admitted to practice in New York.- Christopher Porcelli曾在Aterian, Inc.（纳斯达克：ATER）担任高级法律和人力资源职务，包括总法律顾问、人事主管和公司秘书（2023 – 2025）。此前，他是纽约Sidley Austin LLP并购集团的合伙人，也是纽约Cadwalader，Wickersham & Taft LLP的企业合伙人。他在纽约大学法学院获得法学博士学位，在圣约翰大学获得学士学位，并获准在纽约执业。
- Christopher Porcelli served in senior legal and HR roles at Aterian, Inc. (Nasdaq: ATER), including General Counsel, Head of People & Corporate Secretary (2023–2025). Previously, he was an associate in the M&A group at Sidley Austin LLP in New York and a corporate associate at Cadwalader, Wickersham & Taft LLP in New York. He received his J.D. from New York University School of Law and his B.A. from St. John's University and is admitted to practice in New York.
- Jeffrey M. Busch
Jeffrey M. Busch，自2026年3月起担任公司全资子公司Ignite Proteomics LLC的首席执行官。2014年6月至2025年6月，Busch先生担任Global Medical REIT Inc.（NYSE：GMRE）的创始人、董事长兼首席执行官，该公司是一家由他创立并在纽约证券交易所上市的医疗保健房地产公司。自1999年以来，Busch先生还担任全球公共卫生组织安全血液国际基金会的创始人、总裁和首席执行官。在三十多年的时间里，布希曾在多家生物技术、诊断和医疗技术公司担任董事和高级管理职务，此前还担任过两次美国总统任命，包括担任美国驻日内瓦联合国代表和美国住房和城市发展部部长助理。Busch先生拥有埃默里大学法学院的法学博士学位以及纽约大学的工商管理硕士和商学学士学位。
Jeffrey M. Busch Jeffrey M. Busch, has served as Chief Executive Officer of Ignite Proteomics LLC, a wholly owned subsidiary of the Company, since March 2026. From June 2014 to June 2025, Mr. Busch served as Founder, Chairman and Chief Executive Officer of Global Medical REIT Inc. (NYSE: GMRE), a healthcare real estate company that he founded and took public on the New York Stock Exchange. Since 1999, Mr. Busch has also served as Founder, President and Chief Executive Officer of Safe Blood International Foundation, a global public health organization. Over the course of more than three decades, Mr. Busch has held director and senior executive roles across a number of biotechnology, diagnostics, and medical technology companies, and previously held two U.S. presidential appointments, including service as a United States Delegate to the United Nations in Geneva and as Assistant to the Secretary of the U.S. Department of Housing and Urban Development.- Jeffrey M. Busch，自2026年3月起担任公司全资子公司Ignite Proteomics LLC的首席执行官。2014年6月至2025年6月，Busch先生担任Global Medical REIT Inc.（NYSE：GMRE）的创始人、董事长兼首席执行官，该公司是一家由他创立并在纽约证券交易所上市的医疗保健房地产公司。自1999年以来，Busch先生还担任全球公共卫生组织安全血液国际基金会的创始人、总裁和首席执行官。在三十多年的时间里，布希曾在多家生物技术、诊断和医疗技术公司担任董事和高级管理职务，此前还担任过两次美国总统任命，包括担任美国驻日内瓦联合国代表和美国住房和城市发展部部长助理。Busch先生拥有埃默里大学法学院的法学博士学位以及纽约大学的工商管理硕士和商学学士学位。
- Jeffrey M. Busch Jeffrey M. Busch, has served as Chief Executive Officer of Ignite Proteomics LLC, a wholly owned subsidiary of the Company, since March 2026. From June 2014 to June 2025, Mr. Busch served as Founder, Chairman and Chief Executive Officer of Global Medical REIT Inc. (NYSE: GMRE), a healthcare real estate company that he founded and took public on the New York Stock Exchange. Since 1999, Mr. Busch has also served as Founder, President and Chief Executive Officer of Safe Blood International Foundation, a global public health organization. Over the course of more than three decades, Mr. Busch has held director and senior executive roles across a number of biotechnology, diagnostics, and medical technology companies, and previously held two U.S. presidential appointments, including service as a United States Delegate to the United Nations in Geneva and as Assistant to the Secretary of the U.S. Department of Housing and Urban Development.
- Corinne Pankovcin
Corinne Pankovcin是BlackRock Investment Management公司的首席财务官，财务主管，首席财务官的财务顾问和总经理。在加入公司之前，Pankovcin女士是Finance & Accounting of Alternative Investments公司高级成员，她还担任PineBridge Investments公司（以前美国国际集团（AIG））新兴市场产品组投资首席财务官。2005年到2011年，Pankovcin女士主要负责另类资产管理产品，包括财务报告。她成功负责金融业务各产品团队和协调投资和投资者估值报告。2002年至2005年，她担任Geller & Company公司Business Development and Process Implementations部门主管。加入Geller & Company公司之前，她担任Bessemer Venture Partners公司财务和会计部副总裁。1991年到2001年，她开始在PricewaterhouseCoopers公司就职，担任过企业保证消费者的产品，制造、中间市场行业高级经理。Pankovcin女士持有道林大学工商管理学士学位，霍夫斯特拉大学的mba学位。她是一个注册会计师。
Corinne Pankovcin served as the Chief Commercialization Officer from April 2023 through January 2024. Ms. Pankovcin served as Aditxt, Inc.'s President from September 2021 through April 2023. Ms. Pankovcin served as Aditxt, Inc.'s Chief Financial Officer from July 2020 through August 2021. From December 2015 to July 2019, Ms. Pankovcin was the Chief Financial Officer and Managing Director and Treasurer of Business Development Corporation of America ("BDCA"), a business development company. Prior thereto, from January 2011 to August 2015, Ms. Pankovcin was the Chief Financial Officer and Treasurer of Blackrock Capital Investment Corporation (NASDAQ: BKCC), and a Managing Director of Finance at BlackRock Investment Management LLC. Prior to joining BlackRock, Ms. Pankovcin was a senior member of Finance & Accounting of Alternative Investments and served as Chief Financial Officer for the Global Emerging Markets products group at AIG Capital Partners. Ms. Pankovcin began her career with PricewaterhouseCoopers LLP, where she ultimately held the role of Senior Manager of Business Assurance for Consumer Products, Manufacturing, and Middle Market industries from 1991 to 2001. Ms. Pankovcin earned her B.S. in Accounting from Dowling College and her Master's Degree in Business Administration from Hofstra University. She is a Certified Public Accountant.- Corinne Pankovcin是BlackRock Investment Management公司的首席财务官，财务主管，首席财务官的财务顾问和总经理。在加入公司之前，Pankovcin女士是Finance & Accounting of Alternative Investments公司高级成员，她还担任PineBridge Investments公司（以前美国国际集团（AIG））新兴市场产品组投资首席财务官。2005年到2011年，Pankovcin女士主要负责另类资产管理产品，包括财务报告。她成功负责金融业务各产品团队和协调投资和投资者估值报告。2002年至2005年，她担任Geller & Company公司Business Development and Process Implementations部门主管。加入Geller & Company公司之前，她担任Bessemer Venture Partners公司财务和会计部副总裁。1991年到2001年，她开始在PricewaterhouseCoopers公司就职，担任过企业保证消费者的产品，制造、中间市场行业高级经理。Pankovcin女士持有道林大学工商管理学士学位，霍夫斯特拉大学的mba学位。她是一个注册会计师。
- Corinne Pankovcin served as the Chief Commercialization Officer from April 2023 through January 2024. Ms. Pankovcin served as Aditxt, Inc.'s President from September 2021 through April 2023. Ms. Pankovcin served as Aditxt, Inc.'s Chief Financial Officer from July 2020 through August 2021. From December 2015 to July 2019, Ms. Pankovcin was the Chief Financial Officer and Managing Director and Treasurer of Business Development Corporation of America ("BDCA"), a business development company. Prior thereto, from January 2011 to August 2015, Ms. Pankovcin was the Chief Financial Officer and Treasurer of Blackrock Capital Investment Corporation (NASDAQ: BKCC), and a Managing Director of Finance at BlackRock Investment Management LLC. Prior to joining BlackRock, Ms. Pankovcin was a senior member of Finance & Accounting of Alternative Investments and served as Chief Financial Officer for the Global Emerging Markets products group at AIG Capital Partners. Ms. Pankovcin began her career with PricewaterhouseCoopers LLP, where she ultimately held the role of Senior Manager of Business Assurance for Consumer Products, Manufacturing, and Middle Market industries from 1991 to 2001. Ms. Pankovcin earned her B.S. in Accounting from Dowling College and her Master's Degree in Business Administration from Hofstra University. She is a Certified Public Accountant.